The latest price target for ALX Oncology Holdings (NASDAQ:ALXO) was reported by Piper Sandler on March 6, 2025. The analyst firm set a price target for $9.00 expecting ALXO to rise to within 12 months (a possible 592.31% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for ALX Oncology Holdings (NASDAQ:ALXO) was provided by Piper Sandler, and ALX Oncology Holdings maintained their overweight rating.

The last upgrade for ALX Oncology Holdings Inc happened on March 6, 2025 when Jefferies raised their price target to $3. Jefferies previously had a hold for ALX Oncology Holdings Inc.

The last downgrade for ALX Oncology Holdings Inc happened on December 19, 2024 when Jefferies changed their price target from $12 to $2 for ALX Oncology Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.

While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a maintained with a price target of $8.00 to $9.00. The current price ALX Oncology Holdings (ALXO) is trading at is $1.30, which is out of the analyst’s predicted range.